List view / Grid view

News

New data from ORIGIN

5 October 2012 | By Sanofi

New data from ORIGIN shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population...

Analyses presented at EASD support Trajenta® (linagliptin) as effective and well-tolerated for patients with type 2 diabetes with different background therapies

2 October 2012 | By Boehringer Ingelheim

Boehringer Ingelheim and Eli Lilly and Company today announced results from a large Phase III study and three pooled analyses of Phase III data presented at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting, which support Trajenta® (linagliptin) as effective and well-tolerated for patients with type…